# Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

> **NCT02952586** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 697 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Avelumab
- **OTHER:** Chemoradiation

## Key facts

- **NCT ID:** NCT02952586
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-28
- **Primary completion:** 2019-12-23
- **Final completion:** 2020-08-25
- **Target enrollment:** 697 (ACTUAL)
- **Why stopped:** The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has been crossed.
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952586, "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02952586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*